Abstract:This working paper is hosted by The Berkeley Electronic Press (bepress) and may not be commercially reproduced without the permission of the copyright holder. Summary. Randomized clinical trials are a powerful tool for investigating causal treatment effects, but in human trials there are oftentimes problems of noncompliance which standard analyses, such as the intention-to-treat or as-treated analysis, either ignore or incorporate in such a way that the resulting estimand is no longer a causal effect. One alternative to these analyses is the complier average causal effect (CACE) which estimates the average causal treatment effect among a subpopulation that would comply under any treatment assigned. We focus on the setting of a randomized clinical trial with crossover treatment noncompliance (e.g., control subjects could receive the intervention and intervention subjects could receive the control) and outcome nonresponse. In this article, we develop estimators for the CACE using multiple imputation methods, which have been successfully applied to a wide variety of missing data problems, but have not yet been applied to the potential outcomes setting of causal inference. Using simulated data we investigate the finite sample properties of these estimators as well as of competing procedures in a simple setting. Finally we illustrate our methods using a real randomized encouragement design study on the effectiveness of the influenza vaccine. 1. Introduction The focus of empirical studies in medicine is often to estimate the causal effect of treatments, where randomized clinical trials are considered the most acceptable tool for investigating these causal relationships. But in trials involving human subjects there are oftentimes problems of patient noncompliance, where the patient does not adhere to the treatment assigned. In addition, there is also the problem of nonignorable missing data, where the missing-data mechanism may depend on unobserved data. Standard methods and analyses either ignore these complications, which can lead to biased estimates of causal treatment effect, or account for them in such a way that the resulting estimand can no longer be considered a causal effect of treatment. A statistical framework for causal inference that deals with the issue of noncompliance is based on potential outcomes and was first introduced by Neyman (1923) for randomized studies and later developed by Rubin (1974, 1978) for nonrandomized studies and other forms of inference. Rubin's approach, sometimes referred to as the Ru-bin Causal Model (Holland, 1986), provides a framework for defining the parameters of interest and correctly attributing the …

Evaluating the dependence of a non-leaky intervention's partial efficacy on a categorical mark

PROPORTIONAL HAZARDS MODELS WITH CONTINUOUS MARKS

Intervention treatment distributions that depend on the observed treatment process and model double robustness in causal survival analysis

Post-randomization Biomarker Effect Modification in an HIV Vaccine Clinical Trial

Efficient nonparametric inference on the effects of stochastic interventions under two-phase sampling, with applications to vaccine efficacy trials

Vaccine efficacy for binary post-infection outcomes under misclassification without monotonicity

Efficient nonparametric estimation of the covariate-adjusted threshold-response function, a support-restricted stochastic intervention

Effects Among the Affected

On the analysis of tuberculosis studies with intermittent missing sputum data

Estimand-based Inference in Presence of Long-Term Survivors

Variant Specific Treatment Effects with Applications in Vaccine Studies

Series 2-19-2009 Multiple Imputation Methods for Treatment Noncompliance and Nonresponse in Randomized Clinical Trials

An information‐theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: Application to vaccine evaluation

Randomization for the susceptibility effect of an infectious disease intervention

Locally Efficient Estimation of Marginal Treatment Effects When Outcomes Are Correlated: Is the Prize Worth the Chase?

Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power

Addressing complications of intention-to-treat analysis in the combined presence of all-or-none treatment-noncompliance and subsequent missing outcomes

Markov-Restricted Analysis of Randomized Trials with Non-Monotone Missing Binary Outcomes

Causal Inference for Continuous Multiple Time Point Interventions

Power/sample size calculations for assessing correlates of risk in clinical efficacy trials

Differential losses to follow-up that are outcome-dependent can vitiate a clinical trial: Simulation results